Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Attention Deficit Severe Drops
Brand Name
Attention Deficit Severe Drops
Generic Name
Attention Deficit Severe Drops
Active Ingredient
.gamma.-aminobutyric AcidCategory
alpha-Adrenergic Agonist [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 3 [hp_X]/59mL | LIQUID | ORAL | 63083-2147 |
Detailed information about Attention Deficit Severe Drops
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Attention Deficit Severe Drops, you must consult a qualified healthcare professional.
.gamma.-aminobutyric Acid (GABA) is a primary inhibitory neurotransmitter and pharmacological agent classified across multiple categories, including alpha-adrenergic agonists and insulin analogs, used for metabolic and neurological modulation.
The dosage of .gamma.-aminobutyric Acid varies significantly based on the intended therapeutic outcome and the specific pharmacological pathway being targeted. For general anxiolytic effects, healthcare providers typically suggest a range of 250 mg to 750 mg taken two to three times daily. When used as a sleep aid, a single dose of 500 mg to 1,500 mg taken 30 to 60 minutes before bedtime is common. For metabolic or growth hormone modulation, doses may exceed 3,000 mg per day, but these higher ranges must only be administered under strict clinical observation due to the risk of affecting the adrenergic and insulin systems.
.gamma.-aminobutyric Acid is not universally approved for pediatric use. In specific cases involving neurodevelopmental disorders or growth hormone deficiencies, a specialist may prescribe weight-based dosing (e.g., 10-20 mg/kg). However, because GABA impacts the developing endocrine and nervous systems, it is generally avoided in children unless the benefits clearly outweigh the risks. Always consult a pediatric specialist before administering this agent to anyone under 18 years of age.
Since .gamma.-aminobutyric Acid is primarily cleared by the kidneys, patients with a reduced Glomerular Filtration Rate (GFR) may require lower doses to prevent systemic accumulation. For patients with moderate renal impairment (GFR 30-59 mL/min), a 25% dose reduction is often recommended. In severe renal failure, use may be contraindicated.
While the liver is not the primary site of GABA elimination, hepatic enzymes are involved in the broader metabolic shunt. Patients with Child-Pugh Class B or C cirrhosis should be monitored for signs of hepatic encephalopathy, as exogenous GABA could theoretically interfere with nitrogen binding and ammonia levels.
Geriatric patients often exhibit increased sensitivity to CNS-active agents. Healthcare providers typically start elderly patients at the lowest possible dose (e.g., 100 mg) to minimize the risk of sedation, dizziness, or falls. Age-related declines in renal function must also be factored into the dosing schedule.
If a dose is missed, it should be taken as soon as the patient remembers. If it is nearly time for the next scheduled dose, the missed dose should be skipped. Do not 'double up' or take extra medication to make up for a missed dose, as this increases the risk of adverse adrenergic or sedative effects.
Signs of an overdose of .gamma.-aminobutyric Acid may include extreme drowsiness, blurred vision, rapid heartbeat (tachycardia) due to its adrenergic agonist properties, or profound muscle weakness. In severe cases, respiratory depression or a significant drop in blood sugar (hypoglycemia) may occur due to its insulin-like effects. If an overdose is suspected, contact emergency services or a poison control center immediately. Treatment is primarily supportive, focusing on maintaining airway patency and cardiovascular stability.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance, as the complex interaction between GABA and your body's hormonal systems requires professional monitoring.
Patients taking .gamma.-aminobutyric Acid frequently report mild to moderate side effects as their bodies adjust to the neurological and metabolic changes. These include:
> Warning: Stop taking .gamma.-aminobutyric Acid and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of .gamma.-aminobutyric Acid may lead to pharmacological tolerance, where higher doses are required to achieve the same therapeutic effect. There is also a risk of 'downregulation' of endogenous GABA receptors, which can lead to increased anxiety or insomnia upon discontinuation. Additionally, because of its classification as an 'Androgen' and 'Estrogen Receptor Agonist,' long-term use should be monitored for impacts on reproductive health and bone density.
No FDA black box warnings currently exist specifically for .gamma.-aminobutyric Acid as a single-ingredient entity. However, when used in formulations that include other adrenergic or hormonal agents, clinicians must adhere to the warnings associated with those specific classes. Patients should be aware that the lack of a black box warning does not imply absolute safety; the potent effects on the CNS and endocrine systems necessitate caution.
Report any unusual symptoms to your healthcare provider. Monitoring of liver enzymes and glucose levels may be required during long-term therapy.
.gamma.-aminobutyric Acid is a potent modulator of the central nervous system and various metabolic pathways. It should not be viewed as a simple 'supplement' but as a pharmacologically active agent with the potential to affect heart rate, blood sugar, and hormone levels. Patients with a history of neurological disorders, cardiovascular disease, or endocrine imbalances must use this agent with extreme caution.
No FDA black box warnings for .gamma.-aminobutyric Acid. However, users should be aware that its classification as an alpha and beta-adrenergic agonist means it carries inherent risks for patients with pre-existing cardiac conditions, similar to other sympathomimetic drugs.
Healthcare providers may require the following tests to ensure safe use:
.gamma.-aminobutyric Acid frequently causes drowsiness, dizziness, and blurred vision. Patients should not drive, operate heavy machinery, or engage in potentially dangerous activities until they are certain how the medication affects them. These effects are often most pronounced during the first few days of treatment or following a dose increase.
Alcohol significantly potentiates the inhibitory effects of .gamma.-aminobutyric Acid. Combining the two can lead to dangerous levels of sedation, respiratory depression, and loss of consciousness. It is strongly advised to avoid alcohol entirely while taking this medication.
Do not stop taking .gamma.-aminobutyric Acid abruptly, especially after prolonged use at high doses. Sudden discontinuation can lead to a 'rebound effect,' characterized by severe anxiety, insomnia, tremors, and in extreme cases, seizures. A gradual tapering schedule, supervised by a healthcare provider, is necessary to allow the CNS and endocrine systems to recalibrate.
> Important: Discuss all your medical conditions, including any history of depression, heart disease, or diabetes, with your healthcare provider before starting .gamma.-aminobutyric Acid.
Certain medications must NEVER be used with .gamma.-aminobutyric Acid due to the risk of life-threatening interactions:
.gamma.-aminobutyric Acid may interfere with the results of certain clinical tests:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is the only way to prevent dangerous drug interactions.
.gamma.-aminobutyric Acid must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by a healthcare professional include:
Patients who are sensitive to other amino acid supplements (such as L-Glutamine or L-Theanine) should be monitored closely, as they may exhibit similar sensitivities to .gamma.-aminobutyric Acid. Additionally, because of its classification involving 'Allergenic Extracts,' patients with severe environmental or food allergies should undergo skin testing or a supervised first dose if there is a concern for cross-reactivity.
> Important: Your healthcare provider will evaluate your complete medical history, including any rare genetic metabolic disorders, before prescribing .gamma.-aminobutyric Acid.
.gamma.-aminobutyric Acid is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have suggested that GABA can cross the placental barrier and may influence the development of the fetal nervous system, which relies on a delicate balance of excitatory and inhibitory signals. Furthermore, its classification as an 'Estrogen' and 'Progesterone' modulator suggests it could interfere with the hormonal environment necessary for maintaining a healthy pregnancy. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus.
It is unknown whether exogenous .gamma.-aminobutyric Acid is excreted in human milk. However, endogenous GABA is a natural component of breast milk. The concern with supplementation is that significantly elevated levels in the mother could lead to increased concentrations in the infant, potentially causing excessive sedation or affecting the infant's developing metabolic system. Breastfeeding mothers should consult with a pediatrician before using this agent.
As previously noted, the safety and efficacy of .gamma.-aminobutyric Acid in children have not been established. In pediatric populations, GABA is often involved in 'synaptic pruning' and other critical brain development processes. Introducing exogenous GABA could theoretically disrupt these processes. Its use in children is typically restricted to specialized clinical trials or specific metabolic disorders under the care of a pediatric neurologist.
Elderly patients are at an increased risk for adverse effects from .gamma.-aminobutyric Acid. Age-related decreases in hepatic and renal function can lead to higher plasma concentrations. Furthermore, the geriatric population is more susceptible to the 'alpha-Adrenergic Agonist' effects, which can complicate the management of hypertension or heart failure. There is also a significant concern regarding the risk of falls due to sedation and ataxia (loss of coordination).
For patients with a GFR between 15 and 60 mL/min, dosing should be cautious and monitored. GABA is not effectively cleared by peritoneal dialysis, and its clearance during hemodialysis is not well-characterized. Patients on dialysis should generally avoid high-dose GABA therapy unless specifically directed by a nephrologist.
In patients with mild to moderate hepatic impairment (Child-Pugh A and B), no specific dose adjustment is usually required, but monitoring for CNS changes is essential. In severe hepatic impairment (Child-Pugh C), the risk of exacerbating nitrogen-related metabolic issues makes the use of GABA potentially hazardous.
> Important: Special populations require individualized medical assessment to ensure that the unique pharmacokinetic and pharmacodynamic challenges of these groups are addressed.
.gamma.-aminobutyric Acid primarily acts as an agonist at GABA-A and GABA-B receptors. The GABA-A receptor is a pentameric transmembrane protein that functions as a chloride-selective ion channel. Upon binding, GABA induces a conformational change that opens the pore, leading to hyperpolarization of the postsynaptic neuron. This increases the threshold for excitation, effectively 'quieting' the nervous system.
Additionally, the provided EPC classifications indicate that .gamma.-aminobutyric Acid acts as an agonist at alpha-adrenergic and beta-adrenergic receptors, likely through indirect modulation of catecholamine release or direct binding in peripheral tissues. Its 'Insulin Analog' property is mediated through GABA receptors located on pancreatic alpha and beta cells, where it helps regulate the balance between insulin and glucagon secretion.
The onset of action for oral .gamma.-aminobutyric Acid is typically 30 to 60 minutes, with peak effects occurring at approximately 90 minutes. The duration of the sedative effect is generally 4 to 6 hours. Tolerance can develop with chronic use, as the brain may reduce the number of available GABA receptors (downregulation) to compensate for the increased inhibitory signaling.
| Parameter | Value |
|---|---|
| Bioavailability | 40% - 60% (Highly variable) |
| Protein Binding | < 10% |
| Half-life | 0.5 - 1.5 hours |
| Tmax | 1.0 - 2.0 hours |
| Metabolism | GABA-Transaminase (GABA Shunt) |
| Excretion | Renal (95%), Fecal (< 5%) |
.gamma.-aminobutyric Acid is a non-proteinogenic amino acid. Within therapeutic categories, it is a CNS depressant, anxiolytic, and metabolic modulator. It is related to drugs like Baclofen (a GABA-B agonist) and Gabapentin (which, despite its name, does not bind directly to GABA receptors but affects GABA metabolism).
Common questions about Attention Deficit Severe Drops
.gamma.-aminobutyric Acid is primarily used to manage symptoms of anxiety, stress, and sleep disturbances by promoting a calming effect on the central nervous system. Beyond its neurological uses, it is also explored for its potential to stimulate growth hormone release and support metabolic health, as evidenced by its classification as an insulin analog. Some healthcare providers may also utilize it in protocols for muscle relaxation or to help manage certain types of chronic pain. However, its effectiveness for these conditions can vary significantly between individuals. Always consult a healthcare provider to see if it is appropriate for your specific clinical needs.
The most frequently reported side effects include drowsiness, a mild tingling sensation in the skin (paresthesia), and gastrointestinal upset such as nausea or bloating. Some users also experience a transient shortness of breath or a slight increase in heart rate shortly after taking a dose. These symptoms are generally mild and often diminish as the body becomes accustomed to the medication. However, if these effects persist or become bothersome, it is important to contact your doctor. More serious but less common effects can include profound sedation or changes in blood sugar levels.
No, you should strictly avoid alcohol while taking .gamma.-aminobutyric Acid. Both substances act as depressants on the central nervous system, and combining them can lead to a dangerous synergistic effect. This can result in extreme drowsiness, impaired motor coordination, significantly slowed breathing, and even loss of consciousness. The combination also places additional strain on the liver and kidneys. To ensure your safety and the efficacy of the treatment, it is best to abstain from all alcoholic beverages during your course of therapy.
The safety of .gamma.-aminobutyric Acid during pregnancy has not been clearly established, and it is generally categorized as Pregnancy Category C. This means that while there is no definitive evidence of harm in humans, the potential for adverse effects on fetal neurodevelopment and hormonal balance cannot be ruled out. Because GABA is a critical signaling molecule in the developing fetal brain, introducing exogenous sources could theoretically cause disruptions. Pregnant women or those planning to become pregnant should only use this medication under the direct supervision of a physician who has weighed the risks against the benefits. Alternative treatments with more robust safety data may be recommended.
For acute symptoms like anxiety or difficulty falling asleep, .gamma.-aminobutyric Acid typically begins to work within 30 to 60 minutes of oral administration. Peak concentrations in the blood are usually reached within one to two hours. However, for more complex metabolic or hormonal goals, such as growth hormone stimulation or blood sugar modulation, it may take several weeks of consistent use to observe measurable changes. The speed of onset can also be affected by whether the medication is taken with food, as high-protein meals may delay absorption. Your healthcare provider can help you set realistic expectations for your specific treatment goals.
Stopping .gamma.-aminobutyric Acid abruptly is not recommended, especially if you have been taking high doses for an extended period. Because the brain's receptors may have adjusted to the supplemental GABA, sudden withdrawal can lead to a rebound effect where symptoms like anxiety and insomnia return more severely than before. Other withdrawal symptoms can include tremors, irritability, and in rare, severe cases, seizures. It is always safest to work with your healthcare provider to gradually taper your dose over several days or weeks. This allows your central nervous system to slowly return to its natural state of balance.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. You should never take two doses at once or 'double up' to make up for a missed dose, as this significantly increases the risk of adverse effects like extreme sedation or heart palpitations. Setting a daily alarm or using a pill organizer can help you stay consistent with your medication. If you find yourself frequently missing doses, discuss strategies with your pharmacist or doctor.
There is no strong evidence to suggest that .gamma.-aminobutyric Acid directly causes significant weight gain in most patients. In fact, because of its role as an insulin analog and its potential to stimulate growth hormone, some research suggests it might actually support a healthy metabolism and lean muscle mass. However, because it can increase appetite in some individuals or cause changes in fluid retention, slight weight fluctuations are possible. If you notice rapid or unexpected weight changes while taking this medication, you should discuss them with your healthcare provider. They can help determine if the change is related to the medication or another underlying factor.
.gamma.-aminobutyric Acid can interact with a wide variety of medications, particularly those that also affect the central nervous system or blood sugar levels. It should be used with caution alongside benzodiazepines, antidepressants, and sleep aids, as it can increase their sedative effects. Additionally, because it has insulin-like properties, it may interact with diabetes medications, potentially causing blood sugar to drop too low. It is also known to interact with certain blood pressure medications. Always provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently using.
Yes, .gamma.-aminobutyric Acid is widely available as a generic supplement and is often sold under its common name, GABA. Because it is a naturally occurring amino acid, it is produced by many different manufacturers in various forms, including capsules, powders, and liquids. Generic versions are typically more cost-effective than branded formulations and are required to meet the same purity standards if they are manufactured in a facility that follows Good Manufacturing Practices (GMP). When purchasing a generic version, look for third-party testing certifications to ensure the product contains the amount of GABA stated on the label.
Other drugs with the same active ingredient (.gamma.-aminobutyric Acid)